Gilead And Merck Report Phase 3 Results For Once-Weekly Oral HIV Regimen Islatravir/Lenacapavir; Meets Week 48 Endpoints In ISLEND-1 And ISLEND-2 Trials

Loading news article.

Gilead And Merck Report Phase 3 Results For Once-Weekly Oral HIV Regimen Islatravir/Lenacapavir; Meets Week 48 Endpoints In ISLEND-1 And ISLEND-2 Trials | WAPE

Gilead And Merck Report Phase 3 Results For Once-Weekly Oral HIV Regimen Islatravir/Lenacapavir; Meets Week 48 Endpoints In ISLEND-1 And ISLEND-2 Trials

Article summary

Related companies

Comments —